文献速递急性肾损伤慢性肾脏病肾小球疾病

IgG4相关肾病的治疗标准

IgG4-related kidney disease: treatment standard.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-09

本文是一篇针对IgG4相关肾病(IgG4-RKD)的治疗标准综述,指出该病可表现为小管间质性肾炎、膜性肾病及腹膜后纤维化所致梗阻性肾病,诊断需结合临床、实验室、影像与病理。糖皮质激素为诱导治疗基石,B细胞靶向治疗(尤其利妥昔单抗)在诱导和维持中显示高效,管理应个体化并长期监测。

要点

  • IgG4-RKD诊断需整合临床、实验室、影像与病理,无单一生物标志物足够敏感或特异。
  • 糖皮质激素是诱导治疗基石,但长期使用需考虑毒性及减停策略。
  • 利妥昔单抗在诱导和维持治疗中均显示高效,可用于减少激素用量。

核心结论

  • IgG4-RKD管理应个体化,综合考虑肾脏受累模式、器官功能障碍及可逆性可能性。
  • 糖皮质激素为诱导治疗基石,B细胞靶向治疗(尤其利妥昔单抗)在诱导和维持中高效。
  • 疾病复发性和慢性肾脏病风险要求长期监测。

研究设计与样本

  • 本文为治疗标准综述,整合当前证据及免疫发病机制与临床试验的新见解。

主要发现

  • IgG4-RKD包括IgG4相关小管间质性肾炎、膜性肾病和腹膜后纤维化所致梗阻性肾病。
  • 糖皮质激素诱导治疗通常快速起效,但疾病呈慢性复发性且激素毒性负担重。
  • 传统免疫抑制剂结果有争议,利妥昔单抗在诱导和维持中均显示高效。
  • 腹膜后纤维化所致梗阻性肾病可能需要介入操作联合免疫抑制治疗。

临床怎么用

  • 根据肾脏受累模式、器官功能障碍和可逆性可能性制定个体化治疗方案。
  • 糖皮质激素作为诱导治疗基石,可考虑利妥昔单抗用于诱导和维持以减少激素用量。
  • 梗阻性肾病患者需评估介入操作的必要性并联合免疫抑制治疗。
  • 因疾病复发性和慢性肾脏病风险,需长期随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IgG4-related disease is a systemic, immune-mediated, fibro-inflammatory condition that can affect virtually any organ. IgG4-related kidney disease represents one of the most clinically relevant manifestations and encompasses a spectrum of renal manifestations, including IgG4-related tubulointerstitial nephritis, membranous nephropathy, and obstructive uropathy secondary to retroperitoneal fibrosis. The diagnosis remains challenging and requires integration of clinical and laboratory findings, along with imaging, and histopathology, as no single biomarker is sufficiently sensitive or specific. Although systemic immunosuppressive therapies largely overlap across manifestations, the practical management differs substantially between parenchymal kidney disease and retroperitoneal fibrosis, particularly with regard to mechanisms of kidney injury, the need for interventional procedures, treatment goals, and monitoring strategies. Glucocorticoids are the cornerstone of induction therapy and typically provide rapid clinical responses; however, the chronic-relapsing course of IgG4-related disease and the burden of glucocorticoid-related toxicity have prompted investigation in steroid-sparing strategies. Conventional immunosuppressive agents have been used with controversial results, whereas B-cell-targeting therapies, particularly rituximab, have demonstrated high efficacy in both induction and maintenance settings. Management should ultimately be individualised, taking into account the pattern of renal involvement, organ dysfunction, and likelihood of reversibility. In patients with obstructive uropathy due to retroperitoneal fibrosis, interventional procedures may be required alongside immunosuppressive therapy. Long-term monitoring is essential because of the relapsing nature of the disease and the potential for chronic kidney disease. This Treatment Standard provides a practical, nephrology-oriented framework for the diagnosis, treatment and follow-up of IgG4-related kidney disease, integrating current evidence with emerging insights from immunopathogenesis and clinical trials.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Peyronel F, Palazzini G, Campi R, et al. IgG4-related kidney disease: treatment standard. Nephrol Dial Transplant. 2026. PMID: 42852734. doi:10.1093/ndt/gfag235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。